Firstkind Ltd, manufacturer of the geko™ device, is joining Arab Health 2024 in Dubai to showcase the many benefits of the geko device in the ABHI Pavilion, Hall2 - Pod Stand H50.H.
In 2023 we have been delighted to announce geko™ device reimbursement in the UK - bringing new hope to patients with long standing chronic wounds, and alongside this the results of our recently published multi-centre randomised self-controlled trial that shows the geko device, combined with multi-layer compression, doubles the rate of venous leg ulcer healing vs. compression alone. Supporting the clinical study is independent health economic data that concludes the geko™ device optimises wound care professionals time and resources, resulting in significant cost savings. The unique mechanism of action of the geko device also addresses trauma-based and post-operative oedema in orthopaedic patients.
The size of a small wrist-watch, the geko device is a self-adhesive, wearable neuromuscular electrostimulator that is applied to the surface of the skin just below the knee, over the head of the fibula bone. It delivers a gentle electrical pulse, once per second to the common peroneal nerve, activating the calf and foot muscle pumps, increasing venous, arterial, and microvascular blood flow – effectively replicating the effects of exercise.
The achievement of our 2023 major milestones cements our commitment to the streamlining of wound care through evidence-based clinical and economic efficiency for better patient outcomes and quality of life.
